Catalyst Biosciences Inc (NASDAQ:CBIO) was the recipient of some unusual options trading on Wednesday. Stock investors bought 1,056 put options on the company. This is an increase of approximately 1,220% compared to the average daily volume of 80 put options.
Shares of NASDAQ CBIO opened at $10.62 on Thursday. Catalyst Biosciences has a 52-week low of $4.15 and a 52-week high of $37.00. The company has a market cap of $122.06 million, a price-to-earnings ratio of -1.43 and a beta of 2.32.
Catalyst Biosciences (NASDAQ:CBIO) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.08. Catalyst Biosciences had a negative return on equity of 27.51% and a negative net margin of 2,983.40%. equities research analysts expect that Catalyst Biosciences will post -2.47 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Kalos Management Inc. acquired a new stake in shares of Catalyst Biosciences during the 2nd quarter worth approximately $244,000. Wells Fargo & Company MN raised its position in shares of Catalyst Biosciences by 148.3% during the 1st quarter. Wells Fargo & Company MN now owns 8,940 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 5,340 shares during the period. Quantitative Systematic Strategies LLC acquired a new stake in shares of Catalyst Biosciences during the 2nd quarter worth approximately $120,000. Rhumbline Advisers acquired a new stake in shares of Catalyst Biosciences during the 2nd quarter worth approximately $136,000. Finally, Spark Investment Management LLC acquired a new stake in shares of Catalyst Biosciences during the 1st quarter worth approximately $330,000. Hedge funds and other institutional investors own 67.98% of the company’s stock.
Several analysts have issued reports on the company. Zacks Investment Research upgraded Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research note on Wednesday, July 25th. ValuEngine upgraded Catalyst Biosciences from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. Chardan Capital restated a “buy” rating and set a $35.00 price objective on shares of Catalyst Biosciences in a research note on Tuesday, June 19th. BidaskClub cut Catalyst Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, June 12th. Finally, B. Riley cut Catalyst Biosciences from a “buy” rating to a “neutral” rating and cut their price objective for the company from $44.00 to $12.50 in a research note on Thursday, June 21st. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $19.50.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.
Featured Story: Outstanding Shares, Buying and Selling Stocks
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.